


Allogeneic iPSC Cell Therapy Landscape

A cited research-leadership and momentum snapshot built from current public PubMed records.



Decision use

This packet shows the work Tensorust can deliver for a portfolio team, corporate strategy group, or therapeutic-area owner: a traceable starting point for research diligence, expert mapping, and topic monitoring. It is a real source-limited analysis, not a product mockup.

What the public record helps surface	What this packet does not claim
- Which researchers and institutions repeatedly appear in the current record - Which subtopics dominate the retrieved literature - Where research activity is visible by year - Which records should be opened first	- Investment, clinical, or commercial conclusions - Citation-weighted influence or person identity resolution - Complete coverage of every paper, trial, or company - A substitute for clinical, legal, or investment diligence

Source and method


Query: **allogeneic iPSC cell therapy**. The packet analyzes 270 records published from 2020 through 2026 and retrieved from NLM PubMed. Every cited paper links to its PMID. Research leaders are ranked by recent publication volume in this retrieved set. Generated July 21, 2026.

Tensorust is built for cited, verifiable work from public data. Explore the live engine at tensorust-site.vercel.app.

Research momentum and leadership

Publication volume in the retrieved set is a discovery signal. It is not a measure of clinical authority, influence, or financial relevance.

Publication momentum



Top public research leaders

#	Researcher	Primary public affiliation	Papers
1	Kaneko Shin	Kyoto University	10
2	Li Yan-Ruide	University of California	6
3	Valamehr Bahram	Fate Therapeutics	6
4	Yang Lili	University of California	5
5	Sugita Sunao	Kobe City Eye Hospital	5
6	Mandai Michiko	Kobe City Eye Hospital	5
7	Takahashi Masayo	Kobe City Eye Hospital	5
8	Deuse Tobias	University of California	4
9	Schrepfer Sonja	University of California	4
10	Motohashi Shinichiro	Chiba University	4

Method note: The full paid workflow adds citation weighting, ORCID-led name disambiguation, trial-investigator mapping, competitor filters, and a buyer-defined source scope.

Institution and topic landscape

The tables below are public-record discovery signals that help a team decide where to investigate further.

Leading institutions	Active indexed subtopics
University of California 16 records	Induced Pluripotent Stem Cells 152 records
Kyoto University 16 records	Cell Differentiation 57 records
University of Minnesota 6 records	Mice 46 records
Stanford University School of Medicine 5 records	Immunotherapy, Adoptive 45 records
Century Therapeutics 5 records	Receptors, Chimeric Antigen 37 records
Fate Therapeutics 5 records	Killer Cells, Natural 34 records
Tokai University School of Medicine 4 records	Cell- and Tissue-Based Therapy 33 records
	Neoplasms 30 records

How this scales for a diligence team

Current delivery	Expansion path
Cited research landscapes, KOL and research-leader maps, Counterfactual claim-evidence briefs, public-source PDFs, and a live topic preview.	Cross-source landscapes joining publications with grants, patents, trials, contracts, company activity, supply risk, and recurring monitoring or alerts.

Cited audit trail

Representative recent public records from the same query set. Each title links directly to the underlying PubMed record.

Cited public record	Why it appears
Safety and early efficacy of iPSC-derived motor neuron progenitor cells in subacute spinal cord injury: protocol for a phase I, mu PMID 42419896 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
From iPSC to manufactured iNK cells using CombiCult® screening platform. PMID 42368447 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
Induced pluripotent stem cell-derived natural killer cells: poised for the clinic as an off-the-shelf allogeneic cell therapy. PMID 42305496 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
Mesenchymal stromal cell therapy for systemic lupus erythematosus: mechanisms, clinical translation, and future directions. PMID 42244005 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
Advances in cell therapy for solid tumours: European perspective and future directions. PMID 42099873 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
An innovative treatment for lung cancer using gene-engineered human-induced pluripotent stem cell-derived natural killer cells. PMID 41915242 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
Preclinical efficacy of combination therapy with allogeneic induced pluripotent stem cell-derived invariant natural killer T and alpha PMID 41904478 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
Progress on cell therapy for skeletal muscle disorders. PMID 41871765 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
Stealth designs to overcome allorejection in engineered cell therapy. PMID 41820137 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.

Limits and review standard

The source set is a recent PubMed retrieval, not a systematic review. Records may be incomplete, author names can collide, affiliations may be abbreviated, and publication counts are not citation-weighted. The analysis should be reviewed with the underlying sources before any investment, clinical, legal, regulatory, or partnership decision.

Prepared by Tensorust | cited, verifiable public-data intelligence